Table 2 Seropositive rate and geometric mean titer against poliovirus types 1, 2, and 3 at 24, 36, and 48 months of age following different immunization schedules

From: Immune persistence after different polio sequential immunization schedules in Chinese infants

 

sIPV-bOPV-bOPV

cIPV-bOPV-bOPV

cIPV-cIPV-bOPV

sIPV-sIPV-tOPV

sIPV-sIPV-bOPV

cIPV-cIPV-tOPV

P value

Test method

24 months

        

Type 1

        

Seropositive, n (%)

173 (100%)

170 (100%)

158 (99.40%)

162 (99.40%)

169 (100%)

166 (100%)

0.218

Fisher exact

GMT (95% CI)

938.4 (794.6–1108)

604.5 (515.5–708.7)

453 (372.9–550.2)

473.8 (386.7–580.6)

814.4 (679.2–976.4)

280.5 (232.1–339.1)

<0.0001

ANOVA

Type 2

        

Seropositive, n (%)

62 (35.80%)

125 (73.50%)

143 (89.9%)

163 (100%)

143 (84.60%)

165 (99.4%)

<0.0001

Pearson Chi-Square

GMT (95% CI)

7.1 (6.15–8.2)

18.27 (15–22.26)

33.7 (27.8–40.8)

284.2 (241.4–334.5)

28.66 (23.59–34.82)

266.6 (225.5–315.2)

<0.0001

Kruskal–Wallis test

Type 3

        

Seropositive, n (%)

173 (100%)

170 (100%)

157 (98.7%)

160 (98.20%)

166 (98.20%)

162 (97.6%)

0.111

Fisher exact

GMT (95% CI)

216.5 (181.9–257.6)

214.9 (183.2–252)

279.3 (230.1–339)

189.9 (151–238.7)

285.5 (237–343.8)

185.5 (147.7–232.9)

0.0017

Kruskal–Wallis test

36 months

        

Type 1

        

Seropositive, n (%)

121 (100%)

135 (100%)

161 (99.40%)

164 (99.40%)

160 (100%)

161 (98.8%)

0.712

Fisher exact

GMT (95% CI)

821.8 (681.1–991.6)

500 (416.3–600.4)

425 (351.2–514.3)

446.9 (361.6–552.4)

798.3 (670.1–951.1)

227.2 (184.4–279.8)

<0.0001

Kruskal–Wallis test

Type 2

        

Seropositive, n (%)

47 (38.8%)

104 (77.0%)

148 (91.4%)

164 (99.4%)

137 (85.6%)

162 (99.4%)

<0.0001

Pearson Chi-Square

GMT (95% CI)

8.1 (6.6–10)

22.14 (17.6–27.9)

38.8 (32–47.1)

312.6 (263.4–371)

31.8 (25.8–39.1)

287.9 (242.3–342.2)

<0.0001

Kruskal–Wallis test

Type 3

        

Seropositive, n (%)

121 (100%)

135 (100%)

162 (100%)

159 (96.4%)

155 (96.9%)

157 (96.3%)

0.003

Fisher exact

GMT (95% CI)

168.4 (134.9–210.3)

194.6 (162.7–232.8)

256.2 (215.2–305)

162 (130.4–201.4)

254.5 (208–311.5)

151.9 (121–190.6)

<0.0001

Kruskal–Wallis test

48 months

        

Type 1

        

Seropositive, n (%)

63 (100%)

95 (100%)

111 (99.1%)

118 (100%)

105 (100%)

119 (99.2%)

0.925

Fisher exact

GMT (95% CI)

1214 (948.6–1554)

561.9 (452.7–697.3)

420 (332.6–530.3)

511.8 (409.7–639.3)

799.9 (629.5–1016)

258.1 (204.6–325.7)

<0.0001

ANOVA

Type 2

        

Seropositive, n (%)

37 (58.7%)

78 (82.1%)

99 (88.4%)

118 (100%)

85 (81%)

119 (99.2%)

<0.0001

Pearson Chi-Square

GMT (95% CI)

12 (8.8–16.4)

21.48 (16.56–27.88)

28.5 (22.9–35.5)

186.5 (156.9–221.8)

23.23 (18.58–29.04)

184.9 (153–223.5)

<0.0001

Kruskal–Wallis test

Type 3

        

Seropositive, n (%)

63 (100%)

95 (100%)

112 (100%)

117 (99.2%)

104 (99%)

120 (100%)

0.715

Fisher exact

GMT (95% CI)

249.7 (180–346.2)

208.6 (166.5–261.2)

275.3 (224.1–338.2)

184.1 (146.2–231.7)

294.7 (243–357.3)

165.4 (131.2–208.4)

0.0006

Kruskal–Wallis test

  1. If there are significant differences among groups, the pairwise comparisons are shown in the Supplementary Tables 2 and 3.
  2. tOPV trivalent oral polio vaccine, cIPV conventional inactivated poliovirus vaccine, bOPV bivalent oral polio vaccine, sIPV Sabin strain–based inactivated poliovirus vaccine, CI confidence interval, GMT geometric mean titer.
Back to article page